{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:16:46Z","timestamp":1788401806465,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.vaccine.2018.09.059","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T22:49:00Z","timestamp":1538779740000},"page":"7025-7032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status"],"prefix":"10.1016","volume":"36","author":[{"given":"Nelly R.","family":"Mugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia S.","family":"Magaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Mwaniki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ngure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Celum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared M.","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise A.","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalton","family":"Wamalwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 7","key":"10.1016\/j.vaccine.2018.09.059_b0005","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1016\/j.vaccine.2013.10.003","article-title":"Comprehensive control of human papillomavirus infections and related diseases","volume":"31","author":"Bosch","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.059_b0010","first-page":"e1","article-title":"Age-specific prevalence of infection with human papillomavirus in females: a global review","volume":"S5\u201325","author":"Smith","year":"2008","journal-title":"J Adolesc Health"},{"issue":"6","key":"10.1016\/j.vaccine.2018.09.059_b0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jadohealth.2011.03.010","article-title":"Age-specific prevalence of human papillomavirus infection in males: a global review","volume":"48","author":"Smith","year":"2011","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2018.09.059_b0020","unstructured":"UNAIDS Programme Coordinating Board; 2016 Available from: <http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/20161123_UNAIDS_PCB39_GAP_Analysis_16-18_EN.pdf>."},{"issue":"17","key":"10.1016\/j.vaccine.2018.09.059_b0025","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1097\/QAD.0000000000000455","article-title":"Long-term cumulative detection of human papillomavirus among HIV seropositive women","volume":"28","author":"Massad","year":"2014","journal-title":"AIDS"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2018.09.059_b0030","doi-asserted-by":"crossref","first-page":"F32","DOI":"10.1016\/j.vaccine.2012.07.092","article-title":"The burden of human papillomavirus infections and related diseases in sub-saharan Africa","volume":"31","author":"De Vuyst","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.09.059_b0035","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3018(17)30149-2","article-title":"Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis","volume":"5","author":"Kelly","year":"2018","journal-title":"Lancet HIV"},{"issue":"8","key":"10.1016\/j.vaccine.2018.09.059_b0040","doi-asserted-by":"crossref","first-page":"e015123","DOI":"10.1136\/bmjopen-2016-015123","article-title":"Associations between highly active antiretroviral therapy and the presence of HPV, premalignant and malignant cervical lesions in sub-Saharan Africa, a systematic review: current evidence and directions for future research","volume":"7","author":"Menon","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.vaccine.2018.09.059_b0045","first-page":"266","article-title":"Immune responses to human papilloma viruses","volume":"130","author":"Stanley","year":"2009","journal-title":"Indian J Med Res"},{"issue":"5","key":"10.1016\/j.vaccine.2018.09.059_b0050","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/CCO.0b013e3282c8c84c","article-title":"Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals","volume":"19","author":"Kojic","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.vaccine.2018.09.059_b0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-0-387-46816-7_7","article-title":"Human papillomavirus infection and disease in the HIV+ individual","volume":"133","author":"Cameron","year":"2007","journal-title":"Cancer Treat Res"},{"issue":"3","key":"10.1016\/j.vaccine.2018.09.059_b0060","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/318071","article-title":"Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women","volume":"183","author":"Palefsky","year":"2001","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.09.059_b0065","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1086\/323081","article-title":"Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women","volume":"184","author":"Ahdieh","year":"2001","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2018.09.059_b0070","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/01.AOG.0000210237.80211.ff","article-title":"Group HIVERS. Vulvar, vaginal, and perianal intraepithelial neoplasia in women with or at risk for human immunodeficiency virus","volume":"107","author":"Jamieson","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.vaccine.2018.09.059_b0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0956462413491735","article-title":"Incidence and progression of cervical lesions in women with HIV: a systematic global review","volume":"25","author":"Denslow","year":"2014","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.vaccine.2018.09.059_b0080","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.30866","article-title":"Cervical cancer incidence after up to 20 years of observation among women with HIV","author":"Massad","year":"2017","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.vaccine.2018.09.059_b0085","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1468-1293.2011.00982.x","article-title":"Guidance on vaccination of HIV-infected children in Europe","volume":"13","author":"Menson","year":"2012","journal-title":"HIV Med"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2018.09.059_b0090","doi-asserted-by":"crossref","first-page":"C61","DOI":"10.1016\/j.vaccine.2012.02.040","article-title":"Immunising the HIV-infected child: a view from sub-Saharan Africa","volume":"30","author":"Mphahlele","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2018.09.059_b0095","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1473-3099(04)01106-5","article-title":"Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children","volume":"4","author":"Obaro","year":"2004","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.09.059_b0100","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1542\/peds.2005-2616","article-title":"Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection","volume":"118","author":"Bekker","year":"2006","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2018.09.059_b0105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e3181de8d26","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old","volume":"55","author":"Levin","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"10.1016\/j.vaccine.2018.09.059_b0110","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/infdis\/jis489","article-title":"Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children","volume":"206","author":"Weinberg","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.059_b0115","unstructured":"Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events: DAIDS\/NIH USA; 2014, 2.0, Available from: <https:\/\/rsc.tech-res.com\/docs\/default-source\/safety\/daids_ae_grading_table_v2_nov2014.pdf>."},{"issue":"8","key":"10.1016\/j.vaccine.2018.09.059_b0120","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1128\/CDLI.12.8.959-969.2005","article-title":"Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18","volume":"12","author":"Dias","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"issue":"36","key":"10.1016\/j.vaccine.2018.09.059_b0125","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1016\/j.vaccine.2016.06.049","article-title":"Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children","volume":"34","author":"MacIntyre","year":"2016","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2018.09.059_b0130","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/21645515.2015.1008877","article-title":"Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in sub-Saharan Africa","volume":"11","author":"Mugo","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.09.059_b0135","unstructured":"Merck & Co. I. GARDASIL product information. In: Merck & Co. WS, NJ, editor. Whitehouse Station (NJ): Merck & Co.; 2009."},{"issue":"17","key":"10.1016\/j.vaccine.2018.09.059_b0140","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/sim.2516","article-title":"Conditional power calculations for clinical trials with historical controls","volume":"25","author":"Korn","year":"2006","journal-title":"Stat Med"},{"issue":"40","key":"10.1016\/j.vaccine.2018.09.059_b0145","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1016\/j.vaccine.2016.08.016","article-title":"HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine","volume":"34","author":"Money","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.09.059_b0150","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/cid\/cit319","article-title":"Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women","volume":"57","author":"Kahn","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2018.09.059_b0155","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.vaccine.2013.09.007","article-title":"Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial","volume":"32","author":"Krajden","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.09.059_b0160","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/QAI.0000000000001355","article-title":"Brief report: antibody responses to quadrivalent HPV vaccination in HIV-infected young women as measured by total IgG and competitive luminex immunoassay","volume":"75","author":"Kahn","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"13","key":"10.1016\/j.vaccine.2018.09.059_b0165","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.vaccine.2017.02.021","article-title":"Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: effect of a fourth dose of vaccine","volume":"35","author":"Levin","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.09.059_b0170","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/1055-9965.283.14.1","article-title":"Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women","volume":"14","author":"Viscidi","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"10.1016\/j.vaccine.2018.09.059_b0175","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.vaccine.2013.11.059","article-title":"Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16\/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months","volume":"32","author":"Lazcano-Ponce","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.059_b0180","unstructured":"Comprehensive cervical cancer control - a guide to essential practice: World Health Organization, 2nd ed.; 2014. Available from: <http:\/\/www.who.int\/reproductivehealth\/topics\/cancers\/hpv-vaccination\/en\/>."},{"issue":"5","key":"10.1016\/j.vaccine.2018.09.059_b0185","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3322\/caac.21355","article-title":"Human papillomavirus vaccination guideline update: american cancer society guideline endorsement","volume":"66","author":"Saslow","year":"2016","journal-title":"CA Cancer J Clin"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T12:27:04Z","timestamp":1662208024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18313288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":37,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0264410X18313288"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.059","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}